117347-88-3

Basic information

• Product Name: {2-[1-(4,5-Dimethoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine
• Synonyms: {2-[1-(4,5-Dimethoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine
• CAS NO: 117347-88-3
• Molecular Weight: 370.475
• Mol File: 117347-88-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {2-[1-(4,5-Dimethoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: {2-[1-(4,5-Dimethoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine(117347-88-3)
• EPA Substance Registry System: {2-[1-(4,5-Dimethoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine(117347-88-3)

Safety Data

• Hazardous Substances Data: 117347-88-3(Hazardous Substances Data)

Upstream product

• 106771-59-9 2-(chloromethyl)-N,N-dimethylaniline 
• 117296-78-3 1-(4,5-Dimethoxy-pyridin-2-yl)-1,3-dihydro-imidazole-2-thione 
• 1026851-26-2 1-(2,2-Diethoxy-ethyl)-3-(4,5-dimethoxy-pyridin-2-yl)-thiourea 
• 1000843-61-7 4,5-dimethoxypyridin-2-ylamine 
• 10072-05-6 methyl 2-(dimethylamino)benzoate 
• 4707-56-6 (2-(dimethylamino)phenyl)methanol 
• 394-35-4 methyl 2-fluorobenzoate 

Relevant articles and documents

2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors

Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.